In this study, we provide a molecular signature of highly enriched CD34 þ cells from bone marrow of untreated patients with chronic myelogenous leukemia (CML) in chronic phase in comparison with normal CD34 þ cells using microarrays covering 8746 genes. Expression data reflected several BCR-ABL-induced effects in primary CML progenitors, such as transcriptional activation of the classical mitogen-activated protein kinase pathway and the phosphoinositide-3 kinase/AKT pathway as well as downregulation of the proapoptotic gene IRF8. Moreover, novel transcriptional changes in comparison with normal CD34 þ cells were identified. These include upregulation of genes involved in the transforming growth factorb pathway, fetal hemoglobin genes, leptin receptor, sorcin, tissue inhibitor of metalloproteinase 1, the neuroepithelial cell transforming gene 1 and downregulation of selenoprotein P. Additionally, genes associated with early hematopoietic stem cells (HSC) and leukemogenesis such as HoxA9 and MEIS1 were transcriptionally activated. Differential expression of differentiation-associated genes suggested an altered composition of the CD34 þ cell population in CML. This was confirmed by subset analyses of chronic phase CML CD34 þ cells showing an increase of the proportion of megakaryocyteerythroid progenitors, whereas the proportion of HSC and granulocyte-macrophage progenitors was decreased in CML. In conclusion, our results give novel insights into the biology of CML and could provide the basis for identification of new therapeutic targets.
Introduction
Chronic myelogenous leukemia (CML) is a malignant disorder of the hematopoietic stem cell (HSC) characterized by a reciprocal translocation between chromosomes 9 and 22 (t(9;22)(q34;q11)). 1 The translocation results in formation of the BCR-ABL fusion oncogene encoding a protein with constitutive tyrosine kinase activation, which plays a central role in the pathogenesis of the disease. 2 Numerous mechanisms are involved in the malignant transformation orchestrated by the BCR-ABL oncoprotein. 3 It constitutively activates mitogenic signaling pathways such as rat sarcoma viral oncogene homolog (RAS)/mitogen-activated protein kinase (MAPK) pathways, the janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, phosphoinositide-3 (PI3) kinase pathway and the MYC pathway. In addition, BCR-ABL induces adhesive and cytoskeletal abnormalities resulting in deregulation of proliferation, apoptosis and release of progenitors from bone marrow (BM). 4, 5 Several studies suggest that the expansion of malignant cells in CML is not directly driven by the neoplastic stem cell but by lineage-committed progenitor cells. 6 Interestingly, treatment of patients with the tyrosine kinase inhibitor imatinib results in the persistence of BCR-ABL-positive cells in most of the patients in complete cytogenetic response, suggesting that blocking of BCR-ABL induces an inhibition of progenitor cells, whereas primitive leukemic stem cells are spared. 7 A limitation of the existing data about BCR-ABL-mediated effects is that they are predominantly derived from human and murine BCR-ABL-transformed cell lines and mouse models, 3 which might not be representative for chronic phase CML. The cell population for studying the pathophysiology of CML are certainly primary hematopoietic stem and progenitor cells from patients with CML.
The assessment of primary CML cells by means of gene expression analyses comparing BCR-ABL-positive cells with normal cells, [8] [9] [10] resulted in expression profiles associated with response to therapy [11] [12] [13] [14] [15] or progression to advanced phases of disease. 16, 17 In a previous gene expression study using an array covering 1185 genes, we could confirm some previously described functional effects of BCR-ABL in highly enriched CD34 þ hematopoietic stem and progenitor cells. 8 Although our study gave novel insights into BCR-ABL-induced effects in primary CML cells, no study exists to date, which provides a large-scale expression analysis of chronic phase CML CD34 þ stem and progenitor cells in comparison with the normal counterparts.
Therefore, we examined highly enriched CD34 þ cells from BM of untreated patients with CML in first chronic phase using microarrays covering 8746 genes and refined the molecular signature of hematopoietic stem and progenitor cells in CML.
Materials and methods

Patients and cells
After informed consent BM mononuclear cells were obtained by density centrifugation as previously described 18 from eight healthy volunteers and from nine patients with untreated newly diagnosed Ph þ CML in chronic phase for gene expression analyses as well as from three healthy volunteers and from three patients for subset analyses (patients characteristics: Supplementary Table 1 ). From three of the nine patients (patient numbers 1-3), we also obtained peripheral blood (PB) mononuclear cells. Samples were processed within 2 h following puncture. CD34 þ cells were positively selected using two rounds of midiMACS immunomagnetic separation (Miltenyi Biotec, Bergisch Gladbach, Germany) following Ficoll density centrifugation as described previously. 18 Purities of CD34 þ cells for expression analyses as assessed by flow cytometry varied between 98.9 and 99.9%.
RNA isolation, cRNA labeling and hybridization to microarrays
Total RNA was isolated from CD34 þ cells using the RNeasy Mini-Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The amount of extracted RNA was quantified using the NanoDrop spectrophotometer (NanoDrop Technologies, Welmongton, DE, USA). Total RNA (median: 7.0 mg; range: 0.7-20 mg) was used to generate biotin-labeled cRNA (median: 25 mg; range: 2.1-68 mg) by means of Enzo BioArray HighYield RNA Transcript Labeling Kit (Affymetrix Ltd, UK). Following fragmentation, labelled cRNA was hybridized to Affymetrix HG-Focus GeneChips stained according to the manufacturer's instructions. The quality of extracted RNA and of cRNA was controlled using an Agilent Bioanalyzer 2100 (Agilent Technologies, Waldbronn, Germany).
Quantification, normalization and statistical analysis
For quality control, normalization and data analysis, we utilized the affy package of functions of statistical scripting language 'R' integrated into the Bioconductor project (http://www. bioconductor.org/). Using histograms of perfect match intensities, 5'-3' RNA degradation side-by-side plots, or scatter plots, we estimated the quality of probes and hybridizations. Only samples were included into the analysis, which had a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 3 0 /5 0 ratio below 2. To normalize raw data, we used a method of variance stabilizing transformations. 19 For identification of differentially expressed genes, we used the significance analysis of microarrays (SAM) algorithm v2.23 (http://www-stat.stanford.edu/_tibs/SAM/), which contains a sliding scale for false discovery rate (FDR) of significantly up-and downregulated genes. 20 All data were permuted 1000 times by using the two classes, unpaired data mode of the algorithm. As cutoff for significance an estimated FDR of 0.1% (comparison CML vs normal) or 5% (comparison CML BM vs CML PB) was chosen by the tuning parameter delta of the software. The significance level of each gene was given by the Q-value (lowest FDR at which the gene is called significant). Moreover, a cutoff for foldchange of differential expression of 1.2 was used.
Quantitative real-time reverse transcription-polymerase chain reaction
Corroboration of RNA expression data was performed by realtime reverse transcription-polymerase chain reaction (RT-PCR) using the ABI PRISM 7900HT Sequence Detection System Instrument (Applied Biosystems, Applera Deutschland GmbH, Darmstadt, Germany). Total RNA was reverse transcribed as described previously. 21 PCR was performed in a MicroAmp 
Statistical analysis
For calculation of statistically significant differences between two groups in quantitative real-time RT-PCR and subset analysis the t-test for unpaired samples was used. A Po0.05 was considered to be statistically significant.
Results and discussion
Gene expression signature of CD34 þ cells from patients with CML in chronic phase
Immunomagnetically enriched CD34 þ hematopoietic stem and progenitor cells from BM of nine patients with untreated BCR-ABL-positive CML in chronic phase and from eight healthy volunteers were examined using Affymetrix HG Focus arrays covering 8746 genes. The complete results of our array experiments are available in the gene expression omnibus database (www.ncbi.nlm.nih.gov/geo/; accession no.: GSE5550) according to MIAME standards. 23 Our gene expression analyses fulfilled the recently published consensus guidelines from three European leukemia networks. Figure 1b) . This is in line with our previous findings made with a smaller number of 1185 genes. 8 Interestingly, it is different to normal CD34 þ cells, as we and others had observed differential expression of genes when comparing normal CD34 þ cells from BM with those from PB. 18, 25 In the following, we describe the expression data comparing normal CD34 þ cells with CML CD34 þ cells by allocating genes into functional groups (Table 1) .
CML CD34 þ cells showed a higher expression level of genes involved in BCR-ABL-signaling
First, we were interested in genes encoding substrates of BCR-ABL. 3 We found an upregulation of the BCR-ABL adapter proteins Grb2 and Crkl, of the cytoskeletal protein talin as well as of the signaling molecules STAT3, STAT4, STAT5, VAV3 and the Ras GTPase-activating protein G3BP2 (Table 1 ; Figure 1 ). The Q-value of each gene is o 0.1% (FDR 0.1%). Downregulated genes in CML are indicated by italics. whereas the ERK inhibitor dual-specific phosphatase 1 was downregulated in primary BCR-ABL-positive cells. Of the alternative c-Jun N-terminal kinase (JNK) MAPK pathway the germinal center kinase-related protein (GCKR; MAP4K5) and Rac-1 as well as Rac-2 were higher expressed, suggesting the functional role of the MAPK pathways in BCR-ABL-positive CD34 þ cells as previously shown for BCR-ABL-positive cell lines. [26] [27] [28] The transcriptional target of MAPK pathways MYC was significantly upregulated, which emphasizes the central role of transcriptional MYC activation in BCR-ABL-induced transformation. 29, 30 The heterogenous nuclear ribonucleoprotein K (HNRPK), which positively regulates MYC expression through ERK1/2 activation in blast crisis CML CD34 þ cells, 31 was also upregulated in chronic phase CML CD34 þ cells, suggesting that HNRPK supports MAPK pathway-dependent activation of MYC. Out of the genes involved in the PI3 kinase pathway, besides components of the PI3 kinase itself, its substrate AKT and the downstream molecules nuclear factor-kB and Bcl XL were significantly upregulated in CML CD34 þ cells. Transcriptional activation of Bcl XL might be enhanced by increased expression of STAT5 in leukemic progenitors. 32, 33 Our data suggest that survival and proliferation depends on the PI3 kinase pathway not only in BCR-ABL-transformed murine cells and fibroblasts 34, 35 but also in primary CML CD34 þ cells. 36 In summary, several substrates of BCR-ABL as well as proteins of BCR-ABL signaling pathways were significantly upregulated in primary CML CD34 þ cells indicating that increased signaling is not only based on phosphorylation but also on transcriptional activation of signaling molecules. Our data support the central role of the classical MAPK and the PI3 kinase pathways for BCR-ABL-induced transformation of CML CD34 þ cells.
CML CD34 þ cells showed a higher expression level of proliferation-associated genes and downregulation of the proapoptotic interferon regulatory factor 8
Next, we looked at functional end points of BCR-ABL-signaling such as proliferation, apoptosis and adhesion. In line with activation of mitogenic pathways, several genes encoding for cell cycle promoting proteins were upregulated in BCR-ABLpositive CD34 þ cells such as the cell division cycle proteins 16, 23, 27 and 37, the cyclins H, G1, the cyclin-dependent kinases (CDK) 2, 7 and 8 as well as the CDK2-associated protein. Moreover, the minichromosome maintenance protein 3, the origin recognition complex subunits 2, 4, 5, which are essential for initiation of DNA replication, and the DNA polymerase epsilon 2 and 3 as well as the transcription factor Dp-1 (TFDP1), which dimerizes with the E2F transcription factor and regulates the expression of various promoters involved in cell cycle in normal CD34 þ cells, 37, 38 were also upregulated in CML progenitor cells. This finding is in line with the higher cell cycle activity of CML CD34 þ cells. Figure 1 Differential expression of BCR-ABL substrates and genes involved in BCR-ABL-associated signaling pathways in primary CML CD34 þ hematopoietic stem and progenitor cells. Genes that were covered by our array are displayed by circular symbols. Abbreviations of genes (gene symbols) are explained in Table 1 and Supplementary Table 2 . Significantly up-and downregulated genes are indicated by red and green, respectively, gray indicates no significantly differential expression. Arrows indicate activation of signaling proteins or transcriptional activation of genes, lines with crossbar indicate inhibition of signaling proteins.
With respect to apoptosis-related proteins, we observed a heterogenous picture. On the one hand, the proapoptotic key proteins caspases 3, 6 and 10 and the FAS receptor were significantly upregulated in BCR-ABL-positive CD34 þ cells. On the other hand, the antiapoptotic protein Bcl XL was also upregulated in CML. Moreover, the interferon regulatory factor 8 (IRF8, interferon consensus sequence binding protein) was significantly downregulated in primary CML CD34 þ cells. IRF8 could induce apoptosis in BCR-ABL-positive myeloid cells in mice 40 and IRF8 knock-out mice developed a myeloproliferative syndrome. 41 Recently, it has been shown in BCR-ABLtransformed murine cells that IRF8 antagonizes BCR-ABL by downregulation of bcl-2 and could override imatinib resistance. 42 Thus, our data derived from CD34 þ cells support the hypothesis that BCR-ABL-induced inhibition of apoptosis in primary human leukemic progenitor cells is mediated by downregulation of IRF8. CML CD34 þ cells had an increased expression of focal adhesion proteins and a reduced expression of L-selectin and N-cadherin.
CML progenitor cells have a decreased capability to adhere to BM stroma 4, 5 and are released from BM to PB to a larger extent in comparison to normal progenitor cells. The reasons for this phenomenon are not yet understood. Therefore, we especially looked on differential expression of genes involved in progenitor cell adhesion and migration. The BCR-ABL adapter protein Crkl, which facilitates complex formation with focal adhesion proteins and is involved in regulation of cellular motility 43 was upregulated in CML CD34 þ cells. Among the Crklassociated adhesion proteins vinculin, talin, parvin and filamin were also significantly upregulated in CML (Figure 1 ). Previous studies reported alterations in integrin-mediated cell-adhesion of CML cells. 5, 44 Looking at changes in integrin expression, we found only the integrins aE and a2b to be upregulated. Therefore, there is no evidence for transcriptional activation of most of the integrins in CML CD34 þ cells. However, BCR-ABL could alter integrin-mediated adhesion and signaling by modulation of the functional state rather than by the expression level of the integrin receptors. A finding along this line was the significantly higher expression of the SRC kinase LYN in CML CD34 þ cells. LYN positively regulates CD34 þ cell movement and lowers adhesion of CD34 þ cells to stromal cells by inhibiting the ICAM-1-binding activity of b2 integrins. 45 Increased expression of LYN might therefore be involved in the release of CML progenitor cells into the PB. Additionally, overexpression of LYN was associated with imatinib resistance. 46 Thus, the upregulation of LYN in CML CD34 þ stem and progenitor cells provides the rational for using the combined ABL/SRC kinase inhibitor dasatinib even in therapy naïve patients with CML. Interestingly, several proteins involved in regulation of the actin cytoskeleton were deregulated in CML CD34 þ cells in comparison with normal cells. The BCR-ABL associated cytoskeletal protein, actin-g1, a component of f-actin, that regulates cell adhesion 47,48 had a significantly lower expression level, whereas the regulators of the actin cytoskeleton, Rho GTPases Rac1 and Rac2, were significantly upregulated in CML CD34 þ cells. 49 Additional adhesion molecules, ICAM-4, cadherin 1 (E-cadherin) and the cadherin-associated protein catenin-a1 were upregulated and L-selectin and cadherin 2 (N-cadherin), a molecule involved in the interaction of the stem cell and its niche, 50 were downregulated in CML CD34 þ cells. Finally, the chemokine receptors CXCR4 and CCR2, which are involved in stem cell and monocyte migration, respectively, were significantly downregulated in CML CD34 þ cells explaining previous findings of a reduced stromal-derived factor-1 responsiveness of CML CD34 þ cells. 51, 52 Thus, our expression data reflect the heterogenous results from previous studies with respect to the adhesion defect of CML cells. In summary, our results suggest that the release of progenitor cells in CML into PB might be supported by a downregulation of the chemokine receptors CXCR4 and CCR2 as well as the adhesion molecules L-selectin and N-cadherin.
Upregulation of genes of the TGFb signaling pathway
Activation of BCR-ABL-induced mitogenic signaling can be enhanced by upregulation of growth factors and their receptors. Indeed, upregulation of macrophage colony-stimulating factor, IL1b, IL7 and transforming growth factor (TGF)b1 as well as of the granulocyte-macrophage colony-stimulating factor receptor was observed. In turn, IL7 receptor and FLT3 were significantly downregulated in leukemic progenitor cells. Looking in detail at the TGFb signaling pathway TGFb1 itself as well as SMAD2, SMAD4 and the TFDP1 were significantly upregulated in CML CD34 þ cells. TGFb1 generally suppresses stem cell proliferation and has inhibitory effects on cytokine-induced cell growth in chronic phase CML. 53 On the other hand, autocrine TGFb stimulates early erythropoiesis and reactivates fetal hemoglobin (Hb) synthesis in adult erythroid progenitor cells. 54, 55 As erythropoiesis-associated genes and fetal globin genes were also upregulated in CML progenitor cells (see below), we hypothesize that erythropoiesis and fetal Hb synthesis is activated in chronic phase CML by an autocrine stimulation of the TGFb pathway. Interestingly, the neuroepithelial cell transforming gene 1 (NET1), which is induced upon TGFb stimulation 56 is also upregulated in CML CD34 þ cells. NET1 plays a central role in Rho GTPase (RAC1)-mediated reorganization of the cytoskeleton 57 and activation of the alternative JNK MAPK pathway. 58 Therefore, TGFb-induced NET1 upregulation might enhance the MAPK-mediated mitogenic activation of CML CD34 þ cells.
CML CD34 þ cells showed an expression pattern characteristic for immature stem cells as well as megakaryocyte-erythrocyte progenitor cells
Further, we looked at genes involved in early hematopoiesis and differentiation. We found several genes associated with early HSCs and their self-renewal to be significantly upregulated in CML CD34 þ cells indicating a molecular phenotype of a more primitive hematopoietic progenitor cell. These genes include GATA2, homeo box genes HoxA9 and HoxA10, MEIS1, zinc finger protein Ikaros, Tal-1, lim-finger protein Lmo-2, member of the Polycomb group Bmi-1 and aldehyd dehygrogenase ALDH1A1, which is expressed in long-term reconstituting HSCs and considered to be involved in chemoresistance. 30, 59, 60 Thus, our gene expression data suggest a greater self-renewal capacity of leukemic CD34 þ cells. Overexpression of HoxA9, MEIS1 and PBX3 might be relevant for the malignant transformation of CML CD34 þ cells, as it has recently been shown that Hox-MEIS-PBX complexes drive leukemogenesis in AML. 61 Looking at genes involved in differentiation, we found that GATA1, associated with early myeloid differentiation, was significantly upregulated and myeloperoxidase, neutrophil elastase 2 (ELA2) and C/EBPd, genes expressed during later stages of myeloid differentiation, were downregulated in CML CD34 þ cells. Two of the central genes promoting lymphoid differentiation, GATA3 and IL-7 receptor a, as well as the B-cell differentiation-associated genes terminal deoxynucleotidyltransferase, pre-B lymphocyte gene 1 (VPREB1), B-cell linker (BLNK) and BCL-6 were downregulated in CML CD34 þ cells. On the other hand, erythropoiesis-associated genes such as erythropoietin receptor, Kruppel-like factor 1 and transferrin receptor were higher expressed in CML CD34 þ cells. An interesting finding was an upregulation of fetal Hb components such as Hbg1, Hbg2 and Hbd as well as Hbb, whereas the genes for adult Hb chains Hba1 and Hba2 were not altered indicating an induction of fetal Hb synthesis in CML progenitor cells. The reactivation of fetal Hb synthesis in CML progenitors could be induced by an autocrine activation of the TGFb signaling pathway (see above). 54, 55 In summary, the gene expression signature of CML CD34 þ cells indicates a molecular phenotype of early HSCs with preponderance for megakaryocyteerythroid progenitors rather than for granulocyte-macrophage progenitors (GMP).
The receptor for leptin was upregulated in CML CD34 þ cells Several surface receptors, which have not been mentioned in the context of the previously addressed functional groups were also deregulated in CML CD34 þ cells. As an example, the LEPR, a member of the cytokine receptor superfamily, which signals via activation of JAK2, STAT1, 3 and 5 proteins as well as MAPK pathways and plays an important role for several physiological and pathophysiological processes such as body mass control, metabolic pathways, reproduction, angiogenesis, bone remodelling and immunity 62 showed the greatest level of differential expression in CML CD34 þ cells. In hematopoiesis leptin induces proliferation of hematopoietic cells and stimulates the differentiation of lineage-restricted precursors of the erythrocytic and myelopoietic lineages. 63 LEPR has also proliferative and antiapoptotic activities in AML 64 and had a high expression level in CML blast crisis 65 suggesting a pathophysiological role in leukemia. As LEPR is upregulated in primary CML CD34 þ cells this receptor might activate proliferation and differentiation of leukemic progenitors and might therefore be a suitable target for novel therapeutic approaches. 66 Further differentially expressed surface receptors are shown in Table 1 .
Upregulation of genes involved in fatty-acid metabolism and in the ubiquitin-proteasome system
Other interesting genes, which were upregulated in CML CD34 þ cells, were sorcin that is related to drug resistance and poor prognosis in AML, and the candidate tumor suppressor gene DLC1 (deleted in liver cancer 1), which activates Rho GTPases and modulates the organization of the cytoskeleton. 67 Moreover, the TIMP1 was also upregulated in CML CD34 þ cells. TIMP1 mediates JAK2-, AKT-and PI3 kinase-dependent survival of erythroid cells and is upregulated in leukemic blasts. 68, 69 Hence, TIMP1 overexpression might enhance activation of PI3 kinase-AKT pathway in CML progenitor cells. The SEPP1, which is involved in response to oxidative stress, was downregulated in CML CD34 þ cells. In addition, several genes involved in the ubiquitin-proteasome system, such as the ubiquitin-conjugating enzymes E2M, E2G1, E2G2, E2G3, E2E1, E2N, E2D2, E2D3, the SUMO-1 activating enzyme (UBA2), the F-box protein 7, UBADC1, and the proteasome subunits a-1, -2, -3, -4, -7 and subunits b-1, -2, -5 were significantly upregulated. This supports a previous finding that BCR-ABL induces a proteasome-mediated degradation of inhibitory proteins. 70 We found several genes involved in fatty acid and lipid metabolism to be upregulated in CML CD34 þ cells. For example, the isoenzymes of the long-chain fatty-acid-coenzyme A ligases ACSL 1, 4 and 5, were higher expressed in leukemic CD34 þ cells in comparison to normal cells. As ACSL play a key role in lipid biosynthesis and are expressed in erythrocyte precursors 71 our expression data might reflect a higher proportion of erythroid progenitors in CML CD34 þ cells. Furthermore, fatty acid synthase (FASN), which catalyzes the synthesis of long-chain saturated fatty acids, and hydroxyacyl-coenzyme A dehydrogenasea, which promotes oxidation of fatty acids, were also upregulated in CML. FASN was overexpressed in aggressive breast cancer and inhibition of fatty acid synthesis resulted in cell cycle arrest and apoptosis of tumor cell lines. 72 Thus, a pharmacological inhibitor of FASN such as cerulenin could be useful for inhibition of leukemic cell growth in CML.
Corroboration by quantitative real-time RT-PCR
For corroboration of the microarray data, we assessed the mRNA expression levels of 8 genes. We did not find any discrepancy of array and RT-PCR data and confirmed significantly (Po0.05) differential expression of TAL1, LEPR, GATA1, TIMP1, CRHBP, ELA2, FACL5, SEPP1 (Figure 2 ). This is in line with our gene expression data, which showed a higher expression level of erythropoiesis-associated genes and which exhibited a lower expression level of late myelopoiesisassociated genes. The results also show that the expansion of malignant precursor cells in chronic phase CML does not occur on HSC level. Additionally, the higher expression of stem cellassociated genes such as GATA2 or the Hox genes in CML CD34 þ cells in combination with a smaller proportion of HSC suggests that those genes are transcriptionally activated in CML HSC and might result in an increased self-renewal capacity of those cells.
Our results suggest that the up-and downregulation of differentiation and stem cell-associated genes in CD34 þ cells are due to both, a different subset composition as well as an upregulation of these genes in the respective progenitor cell subset. This shows that although highly enriched CD34 þ cells have been used for gene expression analysis, we are still looking at data from a rather heterogenous cell population.
The reason for the increased proportion of erythroid progenitors (MEP) and upregulation of erythropoiesis-associated genes as well as the reduced proportion of GMP and IL3Ra high progenitors in CML CD34 þ cells in combination with extremely high neutrophil counts and almost normal Hb values in patients with CML is not clear. One might speculate that there is either a differentiation block of late erythropoietic progenitors, a hypothesis that was already published in the late 1970s, 73 or an increase of early erythropoiesis and a reduced proliferation of late erythroid precursors. The latter hypothesis could be explained by the upregulation of components of the TGFb pathway in CML CD34 þ cells (see above), as it has been previously shown that TGFb1 is a paradoxical inhibitor of erythropoiesis that acts by blocking proliferation and accelerating early differentiation. 74 On the other hand, expansion of cells of the myeloid lineage in chronic phase CML might occur on a late neutrophilic precursor level, whereas early progenitor cells fail to expand due to a higher probability of differentiation as already suggested in a previous paper. 75 
Conclusions
In this study, we provide for the first time a genome-wide gene expression signature of highly enriched CD34 þ hematopoietic stem and progenitor cells from patients with CML in chronic phase. Our data show that several of the BCR-ABL-induced transcriptional effects described in cell lines and BCR-ABLtransduced murine cells can also be found in primary CML progenitor cells. Most components of the classical MAPK pathway and the PI3 kinase/AKT pathway and some genes of the alternative JNK and p38 MAPK pathways were upregulated in primary CML CD34 þ cells. This result also shows, that activation of those pathways not only occurs by phosphorylation of proteins but also on a transcriptional level. With respect to genes involved in adhesion and migration, we found a heterogenous picture that reflects the results from previous studies. 3 Moreover, several novel transcriptional changes in comparison with normal CD34 þ cells, which were not described so far in CML and which might be of therapeutic relevance, were identified. These include an upregulation of components of the TGFb signaling pathway, a higher expression level of fetal Hb genes, an upregulation of genes involved in fatty acid and lipid metabolism or interesting candidate genes, such as the LEPR, thrombin receptor (PAR1) or NET1. Additionally, our expression data suggested an altered composition of the CD34 þ cell population in CML with an increase of erythroid progenitors and a decrease of late myeloid progenitor cells, which we could confirm by subset analysis of CML CD34 þ cells. Therefore, one has to keep in mind that the expression profile reflects at least partially the different proportions of cell subsets in the CD34 þ cell population. However, our data can form the basis for future studies on highly enriched CD34 þ lin-CD38-HSC and might help to identify novel stem or progenitor cell-associated targets for supplementation of therapy with imatinib.
